Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q3 2025 (September 30)7holders +1
2new positions
1sold out
$1.64avg. 13F price*
At the end of Q3 2025, 7 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, up 1 from Q2 2025. 2 opened new positions and 1 sold out. The largest holders were State of Wisconsin Investment Board ($4.9M), Bank of New York Mellon Corp ($1.4M) and Sei Investments Co. ($413K).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $30K |
| Exits | 1 | $6.4M |
All 13F filers, Q2 2025 → Q3 2025: 1,022,073 shares bought and 5,800,000 shares sold, net −4,777,927 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| State of Wisconsin Investment Board | 0.01% | Add +50.0% | 3,000,000 | $4.9M |
| Bank of New York Mellon Corp | 0.00% | Reduce -50.0% | 850,000 | $1.4M |
| Sei Investments Co. | 0.00% | No change | 251,000 | $413K |
| Oppenheimer Asset Management Inc. | 0.00% | Add +5.1% | 83,000 | $136K |
| Stephens Inc. | 0.00% | No change | 24,000 | $39K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | New | 13,073 | $21K |
| Fifth Third Bancorp | 0.00% | New | 5,000 | $8K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.